Author:
Jackson Price,Hofman Michael,McIntosh Lachlan,Buteau James Patrick,Ravi Kumar Aravind
Subject
Radiology, Nuclear Medicine and imaging
Reference64 articles.
1. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. The Lancet.
2. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;The Lancet,2021
3. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION);Morris,2021
4. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy;Cameron;Nuclear medicine communications,1999
5. Dosimetry and safety of 177 Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients;Paganelli;European Journal of Nuclear Medicine and Molecular Imaging,2020
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献